Genovese M, et al. - Authors aimed to assess the patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib (a selective JAK 1 inhibitor) during two-phase 2b, 24-week, placebo-controlled studies. Rapid and sustained (to 24 weeks) improvements in health-related quality of life and functional status of patients with active RA were demonstrated to be resulted from the use of filgotinib as methotrexate add-on therapy or as monotherapy.